---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002384"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T19:42:52.168607+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma launches $50M public offering of 22.2M shares at $2.25; plans Phase 2 SSc-ILD study

## Summary
- Gross proceeds ~$50M from 22,225,000 shares at $2.25; underwriters have 30-day option for 3,333,750 additional shares.
- FDA cleared IND for efzofitimod in SSc-ILD; Phase 2 proof-of-concept study planned for 2023.
- Phase 2 study: 28-week, randomized, double-blind, placebo-controlled, 2:2:1 dosing 270 mg, 450 mg efzofitimod or placebo; 25 patients.
- Orphan drug designations: FDA: sarcoidosis (Jan 2022) and systemic sclerosis (Apr 2022); EU: sarcoidosis (Jan 2023).
- Risk factor supplement: no guarantee of orphan drug exclusivity for future indications or jurisdictions.

## SEC filing metadata
- accession: 0000950170-23-002384
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023002384/0000950170-23-002384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023002384/life-20230208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002384
- JSON: https://secwatch.observer/filing/0000950170-23-002384.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.